Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

    Not Recruiting
  • participants needed
  • sponsor
    Canadian Cancer Trials Group
Updated on 5 March 2022
Chris O'Callaghan
Primary Contact
Austin Hospital (3.4 mi away) Contact
+268 other location
systemic therapy
neutrophil count
cancer treatment
lung carcinoma
non-small cell carcinoma


The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

Condition Non-Small Cell Lung Cancer
Treatment Placebo, MEDI4736
Clinical Study IdentifierNCT02273375
SponsorCanadian Cancer Trials Group
Last Modified on5 March 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note